<DOC>
	<DOC>NCT02746952</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of several doses of UCART19 in patient with relapsed / refractory (R/R) acute lymphoblastic leukaemia (ALL) or chronic lymphocytic leukaemia (CLL)</brief_summary>
	<brief_title>Dose Escalation Study to Evaluate the Safety, Tolerability and Biological Activity of a Single Dose of UCART19 in Patients With Relapsed / Refractory (R/R) B-cell Acute Lymphoblastic Leukaemia (ALL) and Chronic Lymphocytic Leukaemia (CLL)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>Male or female participant Age ≥ 16 years Patient with relapsed or refractory CD19 positive Bacute lymphoblastic leukaemia (BALL) or chronic lymphocytic leukaemia Estimated life expectancy ≥ 12 weeks (according to investigator's judgement) Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Previous treatment with investigational gene or cell therapy medicine products CD19 negative Bcell leukaemia Richter's syndrome Burkitt cell acute leukaemia Previous chemotherapy including biologic/targeted therapy or immunological agents (including blinatumomab) within 3 weeks (nitrosoureas within 6 weeks) before Screening</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>